Gregory Bush

Senior Director, Insights And Analytics at BioLineRx

Gregory Bush, MBA, has a diverse work experience spanning over 15 years. Gregory is currently the Senior Director of Insights and Analytics at BioLineRx, a position they have held since September 2022. Prior to that, they worked at Sanofi Genzyme for seven years, starting as a Senior Business Analyst in the Rare Disease division in February 2015. Gregory progressed to roles of increasing responsibility, including Principal Business Analyst and Manager of Business Analytics for the Rare Disease and Multiple Sclerosis divisions, respectively. In October 2017, they became an Associate Director of Business Analytics for Global Rare Disease. In January 2020, they transitioned to an Associate Director of Data Management role, and later in July 2021, they were promoted to Director of Data Management, where they played a key role in overseeing data management operations.

Before joining Sanofi Genzyme, Gregory worked at TJX, a multinational retail corporation, as a Financial Analyst from August 2011 to February 2015. Prior to that role, they worked as a Financial Analyst at M|C Communications, LLC from March 2010 to July 2011. Gregory began their career as a Staff Accountant at Berry, Dunn, McNeil & Parker in July 2008.

Gregory's early work experience includes a summer position as a Vitamin Water Sales Associate at glaceau in 2007.

Overall, Gregory has a strong background in data management, business analytics, and financial analysis across multiple industries, and their MBA degree further enhances their skillset.

Gregory Bush, MBA, completed their Bachelor's degree in Accounting at Babson College from 2004 to 2008. Following this, they pursued a Master of Business Administration (M.B.A.) at the D'Amore-McKim School of Business at Northeastern University, specializing in Health/Health Care Administration/Management. Gregory successfully completed their MBA from 2014 to 2018.

Links

Previous companies

Sanofi logo

Timeline

  • Senior Director, Insights And Analytics

    September, 2022 - present

View in org chart